In Vivo CAR-T Cell Functional Analysis Service after Intravenous Administration of mRNA-liposome Vaccine

The combination of CAR-T with mRNA-liposome vaccines is a novel strategy to enhance the stimulation and efficacy of CAR-T cells targeting solid tumors. To further support the validation of this strategy, Creative Biolabs is dedicated to providing innovative solutions and comprehensive CART functional validation services to meet the needs of global customers.

Solutions for In Vivo CAR-T Cell Functional Analysis after Intravenous Administration of mRNA-liposome Vaccine at Creative Biolabs

The use of mRNA-liposome vaccines for stimulating CAR-T cells in vivo represents a promising approach to overcome the limitations of traditional CAR-T cell therapy for solid tumors. Creative Biolabs offers comprehensive in vivo CAR-T cell functional analysis services to evaluate the specificity, potency, and efficacy of CAR-T cells after intravenous administration of mRNA-liposome vaccines. Our cutting-edge technologies allow for the precise assessment of CAR-T cell expansion, persistence, cytokine response, cytotoxicity activity, and memory T cell formation in response to the mRNA-liposome vaccine combination strategy.

• In Vivo CAR-T Cell Expansion and Persistence Analysis After Intravenous Administration of mRNA-liposome Vaccine

One of the key benefits of mRNA-liposome vaccines is their ability to promote the expansion and persistence of CAR-T cells in the tumor microenvironment. We provide a variety of means (such as real-time cell analysis) to quantitatively characterize the dynamics of CAR-T cell expansion after mRNA-liposome vaccine inoculation and to monitor the long-term persistence of its sustained anti-tumor effects.

Fig.1 Expansion test of CAR-T cells under the repetitive intravenous dosing of target-antigen encoding RNA-LPX in vivo.¹

• In Vivo and Ex Vivo CAR-T Cell Cytotoxicity and Cytokine Response Analysis After Intravenous Administration of mRNA-liposome Vaccine

The cytokine response and cytotoxicity activity of CAR-T cells play a crucial role in tumor eradication. We measured cytokine secretion profiles and cytotoxic activity of CAR-T cells in recognition of target antigens by combining tumor elimination in animal models, specific marker detection of animal samples, cytokine analysis, and other means to provide valuable insights into the functional capabilities of these engineered immune cells.

Fig.2 Ex vivo cytotoxic activity of CAR-T cells sorted from CLDN6-LPX-vaccinated mice against human CLDN6-transduced B16 mouse melanoma cells at indicated E:T ratios.¹

• In Vivo Memory T Cell Formation Analysis After Intravenous Administration of mRNA-liposome Vaccine

Memory T cell formation is essential for establishing durable antitumor immunity. We evaluated the generation of memory T cells in the CAR-T cell population after mRNA-liposome vaccines in vivo by specific detection of multiple cell populations and related markers, and assessed whether this combination strategy enhanced long-term immune memory and the potential for secondary response upon tumor rechallenge.

What We Can Offer

Frequently Asked Question

Q1: What are the advantages of CART in combination with mRNA vaccine and what in vivo validation needs to be paid attention?

A1: One of the main benefits of mRNA-liposome vaccine combination is the capacity to promote the expansion and persistence of CAR T cells in the tumor microenvironment, which will benefit the treatment of solid tumors. Upon antigen-specific priming and boosting by mRNA-liposome vaccine, we need to pay attention to the characterization of different subtypes of CART cells as well in vivo experiments related secondary response upon tumor rechallenge.

If you want to get more information about our function validation service, please don't hesitate to reach out to us.

Reference

1. Reinhard, Katharina, et al. "An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors." Science 367.6476 (2020): 446-453.